Menu
Not yet recruiting NCT07604220

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

— Observational Cardiac Sarcoidosis Sarcoidosis of the Heart Sarcoidosis With Myocarditis Sarcoidosis, Cardiac

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Exosome Analysis.
Who it may be relevant to
Registry conditions: Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.

Interventions

  • Other Exosome Analysis
    Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches

Primary outcome measures

  • Number of successful biomarker validations [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Adults ≥18 years.
  • Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
  • Undergoing FDG-PET as part of standard care.
  • Ability to provide informed consent.

Exclusion criteria

  • Inability to provide informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT07604220 · 26-004241

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗